NYXH
Nyxoah S.A.
NASDAQ · Healthcare · Medical - Instruments & Supplies · BE
$1.62
−7.95%Year over year
Reported trailing growth
- Revenue
- +359.2%
- EBITDA
- -8.5%
- EBIT
- -17.6%
- EPS
- -2.8%
- Free cash flow
- -15.5%
- Operating cash flow
- -17.9%
Forward estimates
Based on analyst estimates
- Revenue
- +178.2%
- EBITDA
- +67.6%
- EPS
- +53.3%
Three-year CAGR
- Revenue
- +48.1%
- EBITDA
- -54.2%
- EBIT
- -41.0%
- Net income
- -52.1%
- EPS
- -30.4%
- Free cash flow
- -23.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026